Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody (JY025) Injection Combined With Gefitinib/Erlotinib as First-line Treatment Phase II and III Clinical Trials on the Efficacy and Safety of Patients With EGFR-mutant NSCLC

NCT04874844 is registered in ClinicalTrials.gov with Beijing Dongfang Biotech Co., Ltd. as lead sponsor.

NCT NCT04874844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04874844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody (JY025) Injection Combined With Gefitinib/Erlotinib as First-line Treatment Phase II and III Clinical Trials on the Efficacy and Safety of Patients With EGFR-mutant NSCLC
Lead sponsor
Beijing Dongfang Biotech Co., Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
July 30, 2021
Completion date
June 30, 2023
Enrollment
420 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc